GenFleet Added to Hang Seng and MSCI Indexes, Boosting Market Profile

Genfleet Therapeutics (Shanghai), Inc. Class H ( (HK:2595) ) has provided an update.

GenFleet Therapeutics (Shanghai) Inc., a China-based biopharmaceutical company, specializes in innovative therapies for oncology, autoimmune and inflammatory diseases, leveraging a fully integrated R&D and manufacturing platform to advance new molecular entities and differentiated clinical programs. Its pipeline aims to position the company among leading biopharma innovators in China and globally, particularly in RAS-targeted therapeutics and other novel treatment modalities.

The company announced that its shares will be added to several major benchmarks, including the Hang Seng Composite Index, Hang Seng Stock Connect Hong Kong Index, Hang Seng Innovative Drug Index and the MSCI Global Small Cap Index, with changes taking effect between late February and early March 2026. Management said the broad index inclusion, which also extends to multiple healthcare and small-cap Hang Seng sub-indices and enables Stock Connect eligibility, is expected to enhance liquidity, diversify the shareholder base and support GenFleet’s long-term development and market presence.

More about Genfleet Therapeutics (Shanghai), Inc. Class H

GenFleet Therapeutics (Shanghai) Inc. is a China-based biopharmaceutical company focused on developing innovative treatments in oncology, autoimmune and inflammatory diseases to address unmet medical needs globally. The company operates an integrated R&D platform covering target discovery, molecular design and evaluation, translational science, clinical development and key manufacturing functions, enabling it to advance new molecular entities and differentiated clinical strategies with significant market potential.

Average Trading Volume: 707,888

Technical Sentiment Signal: Strong Buy

Current Market Cap: HK$11.7B

For detailed information about 2595 stock, go to TipRanks’ Stock Analysis page.